Drugs / Budesonide/formoterol
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06473779 Background | Sep 2024 → Jun 2027 expected | asthma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Budesonide/formoterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06473779 ↗ |
| Route | Inhaled | “AxMP. Oral inhalation.” NCT06473779 ↗ |